Semaglutide Shown to Decrease Cardiac Risk

A new study led by Professor John Deanfield from University College London reveals that Semaglutide, originally a diabetes medication, can significantly reduce the risk of heart attacks and other major cardiovascular events in people who are overweight and have pre-existing heart conditions, including heart failure. This study, published in The Lancet, builds on earlier research showing that weekly injections of Semaglutide can reduce the risk of heart attacks and strokes by up to 20%. Notably, in people with heart failure, the risk of major cardiac events dropped by 28%, and cardiovascular-related deaths fell by 24%.

The SELECT trial, which included over 17,000 participants, demonstrated that Semaglutide’s benefits extend beyond just weight loss and diabetes management, making it a promising option for cardiac protection. While some patients did experience mild gastrointestinal side effects, these were generally manageable with proper guidance and rarely interfered with the overall benefits of the treatment.

This groundbreaking research underscores the importance of Semaglutide as a versatile medication that not only aids in weight loss but also improves cardiovascular outcomes, potentially saving lives.